Real-life outcomes of intravitreal ranibizumab, aflibercept, and dexamethasone implant administrations in patients with treatment-naïve diabetic macular edema

PURPOSE: To investigate optical coherence tomography (OCT) biomarker data on visual recovery in treatment-naïve diabetic macular edema (DME) and follow the results of intravitreal ranibizumab (RNB), aflibercept (AFL), and dexamethasone (DEX) implant administration within the 1st year of the pro re nata treatment regimen. METHODS: One hundred and twenty eyes of 102 patients were enrolled in the study. The patients medical records were analyzed retrospectively. Best-corrected visual acuity (BCVA), central macular thickness (CMT), type of DME, presence of subretinal fluid, number and localization of hyperreflective dots, vitreomacular interface disorders, disorganization of the retinal inner layer (DRIL), inner segment/outer segment (IS/OS) junction-external limiting membrane (ELM) status, intraretinal cyst diameter and localization, and subfoveal choroidal thickness were examined in all patients. RESULTS: A statistically significant increase in BCVA and a decrease in CMT were detected in all treatment groups. When cases were evaluated in terms of BCVA before and after treatment, statistically significant differences were observed in the RNB and AFL groups at 1 and 4 months and in the DEX group during the 1st year. In terms of OCT biomarkers, visual recovery was obtained in cases of intact IS/OS-ELM and non-DRIL patients. In the serous macular detachment group, more visual gain was achieved with the RNB (1 and 4 months) and AFL (1, 4, and 6 months) agents compared to the DEX implant. On the other hand, in the group with cystoid macular edema, more visual gain was achieved with RNB compared to the DEX implant in all months, but more visual gain was achieved only in the 1st month with AFL administration. CONCLUSION: Significant improvement was achieved for both BCVA and CMT in all treatment groups. We expect that OCT-based prognostic factors will become more important in the treatment of DME and will be determining factors in the choice of treatment.

[1]  V. Karabaş,et al.  Evaluation of retinal inflammatory biomarkers after intravitreal steroid implant and Ranibizumab injection in diabetic macular edema , 2021, European journal of ophthalmology.

[2]  P. Nucci,et al.  Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids , 2019, Acta Diabetologica.

[3]  David F Williams,et al.  Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States. , 2018, Ophthalmology. Retina.

[4]  Usha Chakravarthy,et al.  Disorganization of Inner Retina and Outer Retinal Morphology in Diabetic Macular Edema , 2018, JAMA ophthalmology.

[5]  N. Bressler,et al.  Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T , 2017, Current opinion in ophthalmology.

[6]  A. Loewenstein,et al.  OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. , 2017, Ophthalmology.

[7]  Christian Simader,et al.  Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema , 2017, British Journal of Ophthalmology.

[8]  A. Ophir.  Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. , 2017, American journal of ophthalmology.

[9]  Bianca S. Gerendas,et al.  Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA) , 2017, Ophthalmologica.

[10]  L. Yannuzzi,et al.  Visual Acuity Is Correlated with the Area of the Foveal Avascular Zone in Diabetic Retinopathy and Retinal Vein Occlusion. , 2016, Ophthalmology.

[11]  P. Kaiser,et al.  Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. , 2016, Ophthalmology.

[12]  Hyewon Chung,et al.  CORRELATION OF OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI WITH VISUAL OUTCOMES IN DIFFERENT PATTERNS OF DIABETIC MACULAR EDEMA , 2016, Retina.

[13]  A. Kampik,et al.  Evaluation of the New “SAVE” Protocol in Diabetic Macular Edema Over the Course of Anti-VEGF Treatment , 2016, Current eye research.

[14]  A. Wenzel,et al.  Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study , 2015, British Journal of Ophthalmology.

[15]  Sina Farsiu,et al.  Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema. , 2014, American journal of ophthalmology.

[16]  K. Falavarjani,et al.  Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature , 2013, Eye.

[17]  T. Nakazawa,et al.  VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB DEPENDS ON THE OPTICAL COHERENCE TOMOGRAPHIC PATTERNS OF PATIENTS WITH DIFFUSE DIABETIC MACULAR EDEMA , 2013, Retina.

[18]  Ü. Kamış,et al.  Iatrogenic Lens Injuries , 2012, Turkish Journal of Ophthalmology.

[19]  Quan Dong Nguyen,et al.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.

[20]  Francesco Bandello,et al.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. , 2011, Ophthalmology.

[21]  Dominic McHugh,et al.  Optical coherence tomography may be used to predict visual acuity in patients with macular edema. , 2011, Investigative ophthalmology & visual science.

[22]  Lloyd Paul Aiello,et al.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema , 2010, Ophthalmology.

[23]  Hyewon Chung,et al.  Association between photoreceptor integrity and visual outcome in diabetic macular edema , 2011, Graefe's Archive for Clinical and Experimental Ophthalmology.